Moderna curbs investment in vaccine trials due to U.S. backlash, Bloomberg says

Moderna’s (MRNA) chief executive officer said the company doesn’t plan to invest in new late-stage vaccine trials because of growing opposition to immunizations from U.S. officials, Bloomberg’s Gerry Smith reports. “You cannot make a return on investment if you don’t have access to the U.S. market,” Stephane Bancel said in an interview with Bloomberg TV from the World Economic Forum in Davos, Switzerland. Regulatory delays and lack of support from U.S. health officials are making the potential market size “much smaller,” he said.